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Medicine, Utrecht University, Utrecht, The NetherlandsReceived Jan 16, 2020. Accepted for publication Jun 4, 2020.Purpose: Pathologic complete tumor response after chemoradiation in patients with locally advanced rectal cancer (LARC)
is associated with a favorable prognosis and allows organ-sparing treatment strategies. In the RECTAL-BOOST trial, we
aimed to investigate the effect of an external radiation boost to the tumor before chemoradiation on pathologic or sustained
clinical complete tumor response in LARC.
Methods and Materials: This multicenter, nonblinded, phase 2 randomized controlled trial followed the trials-within-cohorts
design, which is a pragmatic trial design allowing cohort participants to be randomized for an experimental intervention. Pa-
tients in the intervention group are offered the intervention (and can either accept or refuse this), whereas patients in the con-
trol group are not notified about the randomization. Participants of a colorectal cancer cohort referred for chemoradiation of
LARC to either of 2 radiation therapy centers were eligible. Patients were randomized to no boost or an external radiation
boost (5  3 Gy) without concurrent chemotherapy, directly followed by standard pelvic chemoradiation (25  2 Gy with
concurrent capecitabine). The primary outcome was pathologic complete response (ie, ypT0N0) in patients with planned sur-
gery at 12 weeks, or, as surrogate for pathologic complete response, a 2-year sustained clinical complete response for patients
treated with an organ preservation strategy. Analyses were intention to treat. The study was registered with ClinicalTrials.gov,
number NCT01951521.
Results: Between September 2014 and July 2018, 128 patients were randomized. Fifty-one of the 64 (79.7%) patients in the
intervention group accepted and received a boost. Compared with the control group, fewer patients in the intervention group
had a cT4 stage and a low rectal tumor (31.3% vs 17.2% and 56.3% vs 45.3%, respectively), and more patients had a cN2
stage (59.4% vs 70.3%, respectively). Rate of pathologic or sustained clinical complete tumor response was similar between
the groups: 23 of 64 (35.9%; 95% confidence interval [CI], 24.3-48.9) in the intervention group versus 24 of 64 (37.5%; 95%
CI, 25.7-50.5) in the control group (odds ratio [OR] Z 0.94; 95% CI, 0.46-1.92). Near-complete or complete tumor regres-
sion was more common in the intervention group (34 of 49; 69.4%) than in the control group (24 of 53; 45.3%; (OR Z 2.74,
95% CI 1.21-6.18). Grade 3 acute toxicity was comparable: 6 of 64 (9.4%) in the intervention group versus 5 of 64 (7.8%)
in the control group (OR Z 1.22; 95% CI, 0.35-4.22).
Conclusions: Dose escalation with an external radiation therapy boost to the tumor before neoadjuvant chemoradiation did
not increase the pathologic or sustained clinical complete tumor response rate in LARC.  2020 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Chemoradiation before a total mesorectal excision (TME)
in patients with locally advanced rectal cancer (LARC)
reduces the risk of local recurrence and leads to downsizing
of the tumor.1,2 In 12% to 31% of LARC patients, no re-
sidual tumor is found in the resected specimen after che-
moradiation, defined as a pathologic complete response
(pCR).3-5 A pCR is associated with a lower risk of recur-
rence and a longer disease-free and overall survival.6
Moreover, TME could potentially have been omitted,thereby avoiding postoperative complications and surgery-
related morbidity. It has been shown that a watch-and-wait
(W&W) approach with regular surveillance in patients with
a clinical complete response is a feasible alternative to
TME.7-9
Higher radiation doses are associated with a higher
probability of pathologic tumor regression, as scored with
the Mandard tumor regression grade.10,11 Dose-escalated
radiation therapy may therefore enhance tumor downsiz-
ing and render more patients eligible for W&W. In a
Couwenberg et al. International Journal of Radiation Oncology  Biology  Physics1010systematic review on the effect of dose escalation to 60
Gy in LARC, a higher pooled pCR rate of 20.4% with
acceptable grade 3 acute toxicity rate of 10.3% compared
with standard chemoradiation.12 Nevertheless, these results
were predominantly based on nonrandomized studies.
In the present trial, the effect of dose-escalated chemo-
radiation was compared with standard chemoradiation on
pathologic or sustained clinical complete tumor response
(ie, a combined outcome of pCR and 2-year sustained
clinical complete response in organ preservation strategies)
in patients with LARC.
Methods and Materials
Study design
RECTAL-BOOST was a pragmatic, multicenter, non-
blinded, screening phase 2 randomized controlled trial
performed in 2 regional Dutch radiation therapy centers
(University Medical Center Utrecht, Utrecht and MAAS-
TRO Clinic, Maastricht), as described previously.13
RECTAL-BOOST followed the pragmatic trials-within-
cohorts design and was conducted within the prospective
data-collection initiative on colorectal cancer (PLCRC)
cohort.14,15 In PLCRC, clinical data are collected from
adult patients with colorectal cancer of all stages. Partici-
pants optionally consent to bio-banking (blood and/or tis-
sue) and questionnaires on patient-reported outcomes and
give broad consent for randomization for future experi-
mental interventions, which means that patients can be
randomized into trials embedded within the cohort in the
(near) future. Only those assigned to the intervention group
are informed about the trial and will be offered the inter-
vention, which they can either accept or refuse. Participants
assigned to the control group are not notified about the trial
and receive treatment as usual, and their clinical data are
used comparatively within the trial. The trials-within-
cohorts design in the RECTAL-BOOST was evaluated
and described in a separate publication.16 Ethical approval
for RECTAL-BOOST and PLCRC was obtained from the
institutional review board and the institutional review
boards of participating institutions. The study was done in
accordance with the trial protocol, Good Clinical Practice
guidelines, and Declaration of Helsinki.
Patients
Eligible patients were cohort participants who had given
consent to patient reported outcomes and broad randomi-
zation for future interventions, and met the following study-
specific criteria: diagnosed with LARC (cT4, cT3 with
distance to the mesorectal fascia of 1 mm and/or cN2
and/or suspicious extramesorectal lymph node metastases),
tumor 10 cm from the anorectal junction (magnetic
resonance imaging [MRI] based), and World Health Or-
ganization 0 to 2. All patients were staged with MRI and inaccordance with the national guidelines.17 Patients with
oligometastatic disease (cM1) referred for chemoradiation
with curative intent were eligible. Exclusion criteria
included presence of inflammatory bowel disease, prior
pelvic radiation therapy, contraindication for MRI or
capecitabine, pregnancy within the last year, and inade-
quate understanding of the national language. At the
beginning of the study, female patients with a rectal tumor
in close proximity to the vagina were excluded because of
expected low coverage of the target volume. This criterion
was removed in December 2015, after further clinical
experience with boost planning. All patients provided
written informed consent for PLCRC participation. Written
informed consent for the RECTAL-BOOST trial was
signed by patients in the intervention group who accepted
the boost intervention, according to the staged-informed
consent procedure.18
Randomization
After enrollment in PLCRC, eligible patients were
randomly assigned (1:1) to standard chemoradiation (con-
trol group) or to a boost before chemoradiation (boost
group). Centralized randomization was performed by the
study investigators or by an authorized delegate of the Trial
Office Imaging Division of the initiating institution. The
allocation sequence was concealed. Patients were ran-
domized using block randomization with variable block
lengths of 4-6-8 patients, stratified by center. Neither in-
vestigators, treating physicians, nor patients were blinded
to treatment allocation.
Procedures
Details of the treatment protocol were described previ-
ously.13 In both treatment arms, target volumes were
delineated on planning CT scans, aided by T2-weighted
MRI and diffusion-weighted imaging (DWI) matched
to the planning CT, or positron emission
tomographyecomputed tomography. Radiation therapy
was administered using a volumetric modulated arc therapy
technique. Chemoradiation consisted of 50 Gy in 25 frac-
tions of 2 Gy, with concurrent capecitabine 825 mg/m2
twice a day for 5 or 7 days per week. The boost intervention
consisted of a sequential, stereotactic boost to the tumor
(excluding bowel lumen) of 15 Gy in 5 fractions in 5
consecutive working days without concurrent chemo-
therapy in the week before the start of chemoradiation.
Delineation of the gross tumor volume (GTV) was based
on T2-weighted imaging and DWI. No clinical target vol-
ume margin was applied around the GTV. The planning
target volume (PTV) included GTV þ 11 mm in the
anteroposterior direction, GTV þ 7 mm in the lateral di-
rection, and GTV þ 13 mm in the craniocaudal direction.
These margins were derived from in-house observations on
tumor movement on daily MRI scans and setup errors. A
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treatment course of 30 fractions (6 weeks) with an equiv-
alent dose in 2-Gy fractions of 66.3 Gy (a/bZ 10 Gy). The
boost dose was aimed at 65 Gy with a maximal point dose
of 80 Gy. Organs at risk (OARs) in the boost planning
included bowel bag (excluding sigmoid), bladder, vagina,
and anal sphincter. OAR constraints took priority over
boost dose, resulting in a lower coverage when the tumor
was near one of the OARs.
All patients (including controls) were treated according
to the same protocol, including target definition, planning
and constraints, and treatment delivery. The planning con-
straints for the combined boost and chemoradiation treat-
ment plan were the same as those for the chemoradiation
treatment plan alone. Quality assurance was performed on
all radiation therapy plans using standardized methods.
Boost planning and delivery were made uniformly between
the 2 participating centers. For position verification, a cone
beam CTwas performed before all boost fractions using the
rectal wall as surrogate for tumor position, before the first 3
fractions of chemoradiation, and weekly thereafter. In case
of bowel distention, the patient was asked to leave the table
and to empty the bowel if possible.
Time-to-response assessment was included in the trial
protocol. Response to treatment was evaluated with MRI at
9 weeks after the last treatment fraction. Surgery was
considered standard treatment and was planned 12 weeks
after completion of chemoradiation. Surgery took place in
the institution from where the patients were referred and
was performed using the principles of TME, including
abdominoperineal resection (APR), low anterior resection
(LAR), or a rectosigmoid resection with permanent stoma
(Hartmann). Several patients with a (near) complete clinical
response, based on MRI and endoscopy, were evaluated for
W&W. Adjuvant treatment is not routinely administered in
patients with LARC, according to the national guidelines.Outcomes
The primary endpoint of the first version of the trial pro-
tocol was pCR, defined as ypT0N0. However, over time,
W&W became more common in patients with a complete
clinical tumor response. We therefore changed the primary
endpoint into a combined endpoint of pCR in patients with
planned TME at 12 weeks after the last radiation therapy
fraction and, as surrogate for pCR, a 2-year sustained
clinical complete response since the last radiation therapy
fraction with absence of locoregional tumor regrowth in
patients with W&W management, based on a previous
study and the evidence that most regrowths develop within
2 years.8,19 Patients with a ypT0Nx after local excision and
no regrowth/recurrent disease within 2 years were consid-
ered complete responders. Patients with progressive disease
after chemoradiation who did not receive TME were
considered noncomplete responders. This amendment was
approved by the ethics committee in March 2017. At thetime of the analysis, one patient with W&W had 23 months
of follow-up but was considered to be a complete
responder.
pCR was assessed by examination of the resected
specimen in the referral hospitals of the participating hos-
pitals and performed according to the national guidelines.17
For patients with pCR, 3 levels were cut on all blocks from
the tumor site and examined for presence of tumor cells.
Pathologists were unaware of treatment allocation. To
confirm protocol adherence, all pathology reports were
reviewed by a dedicated pathologist. Follow-up for W&W
took place in specialized referral centers.
Secondary outcomes included (near) complete Mandard
tumor regression grade (TRG 1-2), (near) complete radio-
logic MRI response, sphincter preservation, acute toxicity
grade 3, surgical complications grade 3, and quality of
life (QOL) during the first 12 months after randomization.
The 5-tier Mandard TRG was assessed according to the
publication of Mandard and only presented in patients who
received planned surgery at 12 weeks.11
Clinical tumor response was assessed by dedicated ra-
diologists using T2-weighted MRI and DWI at 9 weeks
after completion of chemoradiation and in accordance with
the European Society of Gastrointestinal and Abdominal
Radiology guidelines for restaging. Response was classified
as clinical complete response, complete/near-complete
response, residual mass (ycT1-2, ycT3, or ycT4), and
lymph node restaging (ycN0 or ycNþ).20
Sphincter preservation was defined as patients who
received LAR without stoma, had a successfully reversed
temporary stoma, or were treated with an organ preserva-
tion strategy for 2 years. Toxicity was assessed weekly
during treatment and at 4 and 9 weeks after completion of
treatment by the radiation oncologist using the Common
Terminology Criteria for Adverse Events (CTCAE) version
4.0. Surgical complications were categorized according to
ClavieneDindo classification and included anastomotic
leakage, abscess, bleeding, ileus, dehiscent fascia, iatro-
genic injury to bowel and ureter/urethra, and other non-
specified complications. QOL was measured with the
European Organisation for Research and Treatment of
Cancer (EORTC) core cancer questionnaire (QLQ-C30) at
baseline (at time of randomization) and at 3, 6, and 12
months.21 Serious adverse events were registered for pa-
tients in the intervention arm from start of radiation therapy
until 8 months.Statistical analysis
We estimated that 30% of the patients in the boost group
would achieve a pCR versus 13% in the control group.10
Patients allocated to the intervention arm may refuse the
boost intervention, which would dilute the outcome in an
intention-to-treat analysis.22 The sample size was therefore
adjusted for the estimated proportion of patients refusing
the intervention, which was in the present trial estimated to
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patients per arm, based on a one-sided test (aZ 0.15, and
power Z 80%), corrected for a refusal rate of 20%. We
used a one-sided test and higher a as recommended for
phase 2 screening trials.23 After enrollment of the 100th
patient, the refusal rate in the intervention arm was evalu-
ated.24 Because the refusal rate was slightly higher than
expected, we adapted the sample size from 120 to 128
patients.
The primary outcome was analyzed with a c2 test. Lo-
gistic regression was used to calculate odds ratios (ORs)
with 95% confidence intervals (CIs). Adjusted analysis was
performed in case of imbalance in baseline characteristics,
as suggested in the literature.25
Secondary objectives with a categorical outcome were
analyzed with a c2 test, and effect sizes were presented in
OR with 95% CI. QOL was compared between the treat-
ment groups using the EORTC QLQ-C30 summary score,
which is a weighted score based on 13 domains/scales of
the questionnaire and captures functioning, global health,
and general cancer symptoms.26 A linear mixed-model was
used with a random intercept, an autoregressive covariance
structure of the first order, and included time, treatment
group, and its interaction. Outcomes were presented in
mean differences (MDs) with 95% CI.
Data were analyzed based on the intention-to-treat
population. However, for Mandard TRG 1 to 2 and
ClavieneDindo surgical complications we only analyzed
the patients who received surgery. Differences with a
P value <.05 were considered statistically significant,
except for the primary endpoint, where P < .15 had been
prespecified. Data were analyzed with Statistical Package
for Social Sciences (SPSS) version 25. An independent data
and safety monitoring board periodically assessed safety
data, including radiation toxicity and surgical complica-
tions. After the first 10 patients treated with dose-escalated
chemoradiation followed by LAR, enrollment of patients
with a midrectal tumor planned for LAR was paused for
8 months to evaluate safety of the intervention in terms of
anastomotic leakage.
The trial was registered with Clinicaltrials.gov, number
NCT01951521. The cohort was registered with the number
NCT02070146.Results
Between September 11, 2014 and July 13, 2018, 64 patients
were randomly assigned to the control group and 64 to the
intervention group (Fig. 1). Of the 64 patients in the
intervention group, 51 (79.7%) patients accepted and un-
derwent the intervention. Twelve (18.8%) patients refused
to undergo the intervention and received standard chemo-
radiation. One patient accepted the intervention but did not
receive a boost due to a very minimal target coveragebecause of a small bowel constraint. It was therefore
considered unethical to have this patient come to the hos-
pital for 5 additional visits.
Baseline characteristics were well balanced in terms of
age, sex, presence of comorbidities, and MRF involvement
(Table 1). An imbalance between the control group
and boost group was observed in distally located tumors
(n Z 36, 56.3% vs n Z 29, 45.3%, respectively), cT4 stage
(n Z 20, 31.3% vs n Z 11, 17.2%, respectively), and cN2
stage (n Z 38, 59.4% vs n Z 45, 70.3%, respectively). The
prescribed capecitabine dose was similar between the
groups (3300 mg/day in each group). Median interval to
MRI was 9 weeks, and median interval to surgery was 12
weeks in both groups.
Median tumor volume (based on the number and volume
of voxels within the delineated tumor at planning CT) was
comparable between the treatment groups (33 mL [inter-
quartile range, 20-47] in the boost arm vs 35 mL [inter-
quartile range, 25-57] in the control arm). Planned mean
dose to the PTV of the tumor was 66.8 Gy in the boost
group and 50.0 Gy in the control group (Table 2). All pa-
tients in the boost group completed the 5 boost fractions.
Sixty (93.8%) patients completed the entire radiation
schedule and 60 (93.8%) completed the prescribed cape-
citabine dose versus 63 (98.4%) and 61 (95.3%) in the
control arm, respectively. Three patients in the boost arm
and 1 patient in the control arm missed the last treatment
fraction. One patient in the boost arm missed 2 fractions. In
2 patients (boost arm), missing fractions were related to
acute toxicity.
Planned surgery at 12 weeks after completion of CRT
was received by 49 (76.6%) patients in the boost group and
53 (82.8%) patients in the control group (Table 2). In the
boost group, 28 (43.8%) patients underwent LAR, 18
(28.1%) patients APR, 2 (3.1%) patients a Hartmann, and 1
(1.6%) patient a local excision. In the control group, 32
(50.0%) patients underwent APR, 19 (29.7%) patients
LAR, and 2 (3.1%) patients a Hartmann. Three patients in
the boost group and 3 patients in the control group with a
clinical near-complete response were evaluated for W&W
but received delayed surgery because of a residual tumor
(none of these patients had a complete response at patho-
logic assessment). One patient with a W&W approach in
each group developed local tumor regrowth, both at 1 year
after chemoradiation. The patient in the boost group
received salvage APR, and the patient in the control group
underwent a salvage local excision (ypT3) followed by
completion APR. In total, 9 W&W patients in the boost
arm and 5 W&W patients in the control arm had a 2-year
sustained clinical complete response. In both groups, 2
patients had distant progressive disease at time of response
MRI and received palliative systemic treatment.
Pathologic or 2-year sustained clinical complete tumor
response rate was similar between the boost and control
group: 23 of 64 (35.9%; 95% CI, 24.3-48.9) in the inter-
288 rectal cancer patients 
referred for chemoradiation
200 eligible for the trial
88 excluded
- 78 did not meet the in/exclusion criteria
- 10 planned during stop for sphincter sparing 
resection to evaluate safety of the intervention
128 eligible cohort 
participants randomised
64 intervention group 64 control group
64 included in intention-to-
treat analysis
64 received standard 
chemoradiation
51 received the intervention
64 included in intention-to-
treat analysis
12 refused the intervention
1 no intervention applied
65 did not consent to the cohort
13 received standard 
chemoradiation
190 enrolled in the cohort







Fig. 1. Flowchart of eligible and randomized patients.
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in the control group (OR Z 0.94; 95% CI, 0.46-1.92;
P Z .86). In the boost group, 13 patients had a pCR, 9
patients had a W&W with a 2-year sustained clinical
complete response, and 1 patient had a ypT0Nx after a local
excision with 2-year freedom from regrowth/recurrent
disease. In the control group, 19 patients had a pCR and 5
patients had a W&W with a 2-year sustained clinical
complete response.
A multivariable analysis, including treatment allocation
and the imbalanced baseline characteristics (ie, cT-stage,
cN-stage, and tumor location), showed no significant effect
of any of the factors nor a significant primary outcome
(Table E1). The per-protocol analysis showed a pathologic
or 2-year sustained clinical complete tumor response in 18
of 51 (35.3%) patients treated with dose-escalated chemo-
radiation and 29 of 77 (37.7%) patients treated with stan-
dard chemoradiation (OR Z 0.90; 95% CI, 0.43-1.89; P Z
.79).
Clinical complete/near-complete tumor response (ie,
ycT0[near]ycN0) at MRI was not significantly different be-
tween thegroups: 18 of 64 (28.6%)patients in the boost group
versus 12 of 64 (18.8%) in the control group (OR Z 1.73;
95% CI, 0.75-3.98) (Table 3, Table E2).Sphincter preservation was more often achieved in the
boost group than in the control group: 36 of 64 (56.3%)
versus 22 of 64 (34.4%) (OR Z 2.46; 95% CI, 1.20-5.01)
(Table 3).
Of all patients who underwent planned surgery, a higher
rate of (near) complete tumor regression was observed in
the boost group compared with the control group: Mandard
TRG 1 to 2 in 34 of 49 (69.4%) versus 24 of 53 (45.3%) in
the control group (OR Z 2.74; 95% CI, 1.21-6.18)
(Table 3, Table E3).
The most common CTCAE acute toxicities included
diarrhea/proctitis, fatigue, dermatitis, and cystitis nonin-
fectious (Fig. 2). Grade 3 toxicity was comparable be-
tween the groups: 6 of 64 (9.4%) in the boost group versus
5 of 64 (7.8%) in the control group (OR Z 1.22; 95% CI,
0.35-4.22) (Table 3). The proportion of patients with diar-
rhea/proctitis toxicity grade 1 to 2 in the boost group was
higher (57.8% vs 42.4% in the control group). Two patients
in the boost arm had grade 4 toxicity. One patient devel-
oped capecitabine-related panenteritis and was admitted to
intensive care (no DPD deficiency was demonstrated). One
patient with mucosal bleeding developed acute renal failure
after contrast injection for CT, which was temporarily
treated with dialysis. None of the patients in the control arm











Male 48 (75.0) 47 (73.4)
Female 16 (25.0) 17 (26.6)
Comorbidities
None 30 (46.9) 26 (40.6)
1 or more 34 (53.1) 38 (59.4)
Tumor distance*
<3.0cm 29 (45.3) 36 (56.3)
3.1-5.0 cm 12 (18.8) 8 (12.5)
5.1-10.0cm 23 (35.9) 20 (31.2)
Tumor stage
cT2 2 (3.1) 5 (7.8)
cT3 51 (79.7) 39 (60.9)
cT4 11 (17.2) 20 (31.3)
Distance to the mesorectal
fasciay
1 mm 42 (65.6) 46 (71.9)
>1 mm 22 (34.4) 18 (28.1)
Nodal stage
cN0 5 (7.8) 9 (14.1)
cN1 14 (21.9) 17 (26.6)
cN2 45 (70.3) 38 (59.4)
Oligometastatic disease
No 61 (95.3) 62 (96.9)







Interval to MRI, wkz 9.0 (8.0-9.0) 9.0 (8.0-9.0)




Data presented as number (%) or median (interquartile range).
* Measured from the anorectal junction on sagittal magnetic reso-
nance imaging.
y Based on the primary tumor.
z One patient in the boost group did not undergo the response
magnetic resonance imaging because of anxiety symptoms.



































Low anterior resection 28 (43.8) 19 (29.7)
Abdominoperineal resection 18 (28.1) 32 (50.0)
Hartmann resection 2 (3.1) 2 (3.1)
Local excision 1 (1.6) 0
Delayed/salvage surgeryz
Low anterior resection 1 (1.6) 2 (3.1)
Abdominoperineal resection 1 (1.6) 2 (3.1)
Local excision 2 (3.1) 0
2-y watch-and-wait 9 (14.1) 5 (7.8)
Palliative systemic treatment 2 (3.1) 2 (3.1)
Abbreviation: PTVtumor Z planned target volume of the tumor.
Data presented as median (interquartile range) or n (%).
* Planned mean dose to the PTV.
y Minimum dose is the highest dose received by 99% of the PTV
(D99) and the maximum dose is the highest dose received by 1% of the
PTV (D1).
z Includes patients with a (near) complete clinical response after
chemoradiation and evaluated for a watch-and-wait strategy but who
received surgery because of a nonsustained complete response at first
watch-and-wait follow-up assessment (referred to as delayed surgery
for near-complete responders), or at later follow-up assessment
(referred to as salvage surgery for regrowth).
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observed.
Of all patients who underwent surgery, occurrence of
ClavieneDindo grade >3 surgical complications was not
statistically significant between the groups: 14 of 53
(26.4%) in the boost group versus 11 of 57 (19.3%) in the
control group (OR Z 1.50; 95% CI, 0.61-3.68) (Table 3).
One (1.6%) patient in the boost group died of a cardio-
pulmonary event <30 days after APR with partial sacrum
resection, which was judged to be unrelated to the boost
intervention.
EORTC QLQ-C30 response rates at the different time
points ranged between 68.8% and 92.2% in the boost group
and 67.2% and 89.1% in the control group. The summary
score showed a significantly lower score in the boost group
at 3 months after randomization (MD with the controlgroup Z e7.5 [95% CI, 3.0-12.1]; P Z .001) (Table 3,
Fig. 3). At baseline and 6 and 12 months, QOL was com-
parable between the groups.Discussion
This trial may indicate that a radiation therapy boost of 15
Gy to the tumor before standard-dose chemoradiation does
not lead to more pathologic or sustained clinical complete
tumor responses in patients with LARC. However, signifi-
cantly more (near) complete tumor regression (Mandard
TRG 1-2) and sphincter preservation was observed in the
dose-escalated chemoradiation group. Severe acute toxicity
and surgical complications were comparable between both
groups, but QOL was worse at 3 months after randomiza-
tion in the boost group.
In a previous publication, a clear dose-response rela-
tionship in LARC was demonstrated for tumor regression
after preoperative chemoradiation for tumor dose levels in







(95% CI) boost vs control P value*
pCR or 2-y cCR 23 of 64 (35.9) 24 of 64 (37.5) 0.94 (0.46-1.92) .86
ycT0(near)ycN0 at response MRIy 18 of 64 (28.1) 12 of 64 (18.8) 1.73 (0.75-3.98) .21
Sphincter preservation 36 of 64 (56.3) 22 of 64 (34.4) 2.46 (1.20-5.01) .01
Mandard TRG 1-2z 34 of 49 (69.4) 24 of 53 (45.3) 2.74 (1.21-6.18) .02
CTCAE grade 3 6 of 64 (9.4) 5 of 64 (7.8) 1.22 (0.35-4.22) .75
ClavieneDindo grade 3 14 of 53 (26.4) 11 of 57 (19.3) 1.50 (0.61-3.68) .50
QoL summary scorex
Baseline 87.7 (1.6) 86.3 (1.6) 1.31 (e5.81 to 3.18) .57
3 mo 80.8 (1.6) 88.4 (1.7) e7.54 (e12.09 to e2.99) .001
6 mo 78.5 (1.7) 82.2 (1.7) e3.64 (e8.28 to 1.00) .12
12 mo 87.0 (1.8) 87.5 (1.8) e0.57 (e5.56 to 4.42) .82
Abbreviations: cCR Z clinical complete response; CI Z confidence interval; CTCAE Z Common Terminology Criteria for Adverse Events;
MD Z mean difference; OR Z odds ratio; pCR Z pathologic complete response; QoL Z quality of life; Ref Z reference group; TRG Z tumor
regression grade.
Data presented as n (%) or mean (standard error) for quality-of-life scores.
* Based on c2 test.
y One patient in the boost group did not receive a response MRI because of new-onset claustrophobia.
z Presented in patients treated with planned surgery at 12 weeks.
x Presented as mean difference (95% confidence interval).
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Fig. 2. Common Terminology Criteria for Adverse Events (CTCAE) acute toxicity by allocated treatment. Presented is the
highest toxicity grade (gr) per patient during and/or shortly (9 weeks) after chemoradiation.
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Fig. 3. European Organisation for Research and Treat-
ment of Cancer (EORTC) core cancer questionnaire (QLQ-
C30) quality-of-life summary score by allocated treatment
at randomization and at 3, 6, and 12 months after. The
summary score is a weighted score of 13 items of the
questionnaire and captures functioning, global health, and
general cancer symptoms. Statistically significant differ-
ence between the boost group and control group is denoted
with an asterisk.
Couwenberg et al. International Journal of Radiation Oncology  Biology  Physics1016the range of 50.4 to 70 Gy.10 In contrast, we observed no
increase in complete response rate after dose escalation
from 50 to 65 Gy. The study in question was partly based
on data from a randomized phase 3 trial, where the addition
of brachytherapy boost to standard dose chemoradiation did
increase the rate of complete and near-complete response,
but not the rate of pCR.27 The subsequently estimated dose-
response curve used ordinal logistic regression for assess-
ing the relationship between dose and TRGs 1 to 4 (not
specifically on pCR). The reported dose-response associa-
tion may thus mainly be driven by TRG 1 to 2, which
would support our findings. Yet, it remains unclear why
dose escalation leads to more tumor regression but not a
complete response. In the present trial, it might partly be
explained by the limited boost dose to the PTVof the tumor
due to its location near one of the OARs (as shown by the
minimum dose), which could have diluted the boost effect.
Time between the completion of chemoradiation and
(pathologic) response assessment could also play a role,
suggesting that near-complete response may become a
complete response by awaiting further response, as previ-
ously supported.28,29
Surprisingly, the rate of complete response after stan-
dard chemoradiation that we observed was much higher
than reported in literature, especially considering the
advanced stage.3,4 This may partly be explained by tumor
size. Tumor volume, as well as nodal stage, has an effect on
the dose-response relationship, with smaller-volume tumors
and absence of pathologic lymph nodes demonstrating
higher probability of tumor regression.10 In the present
trial, patients had a median tumor volume of 35 mL
(comparable between the groups), which is relatively smallwhen compared with, for example, the previously discussed
phase 3 trial.27 The national colorectal cancer screening
program aims to detect (advanced) tumors earlier, which
may have led to smaller tumor volumes compared with
those observed in historical cohorts. Nodal stage is rather
unlikely to explain the high response rate because most of
the patients participating in this trial had node-positive
disease. In addition, quality of diagnostic MRI differs
among studies and has improved over the past years, which
could have resulted in stage migration. The 12-week time
interval to surgery may also partly explain the high
response rate. Several studies have shown a positive asso-
ciation between time interval and pCR.3,4 Thus simply on
the basis of the 12-week interval from end of radiation
therapy to surgery, compared with the 6 to 8 weeks most
commonly used, one would expect the complete response
rate to be higher than in other trials.12,30
Acute toxicity grade 3 to 4 was similar between the
treatment arms and comparable with the literature.12
Nevertheless, more grade 1 to 2 toxicity was observed in
the boost arm, which was mainly bowel-related toxicity
including proctitis, diarrhea, and mucosal bleeding. Patients
in the boost group had a lower QOL at 3 months after
randomization. Nevertheless, this effect was temporary, and
the 2 groups were equivalent at 6 and 12 months. The effect
could have been affected by the nonblinded nature of the
trial.
We observed a higher rate of sphincter preservation in
the boost group than in the control group. This is a prom-
ising finding because a permanent stoma can affect pa-
tients’ life severely. However, this outcome should be
interpreted with caution because there is likely an associ-
ated selection bias. At the time of the present trial, organ
preservation was not actively offered by all surgeons to all
patients with a clinical complete response. As a result,
(non)surgical treatment was very much based on preference
and not on the effect of the treatment or intervention.
Furthermore, the control group was not informed about the
present trial and may therefore have had less awareness of
the possibility of organ preservation after a clinical com-
plete response.
The results of this trial are aligned with previous ran-
domized trials.27,31 Published recently, the INTERACT trial
was a phase 3 trial investigating the effect of an integrated
radiation boost (10  1 Gy) during chemoradiation versus
chemoradiation with oxaliplatin on Mandard TRG 1 to 2 in
LARC. The TRG 1 to 2 rate was significantly higher in the
radiation boost group (62% vs 52%), and the pCR rate was
similar (24% in both groups). Nevertheless, the
INTERACT trial excluded cT4, used a lower boost dose,
performed surgery earlier (after 7-9 weeks), and did not
include a standard treatment group, which makes the trials
less comparable. The previously mentioned Danish phase 3
trial observed a similar pCR rate between the dose-
escalated chemoradiation group and the standard arm
(18% in both groups), but more TRG 1 to 2 (44% vs
28%).27 Some nonrandomized studies have shown high
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endorectal radiation techniques, including high-dose-rate
endorectal brachytherapy or x-ray contact therapy.32,33
This is likely the result of the higher radiation dose ach-
ieved within the tumor using these techniques. Unfortu-
nately, endorectal radiation may not be suitable for large
tumors and is associated with bleeding toxicity.
This trial has several limitations. Randomization was not
stratified by clinical tumor characteristics, which resulted in
differences between the groups in cT stage, cN stage, and
tumor location, and the choice for adjusted analysis.
Furthermore, we redefined the endpoint because progress in
organ-sparing treatment approaches had caught up with our
primary stated endpoint. However, 2-year freedom from
locoregional regrowth may not directly translate into pCR.
Patients with a clinical complete response may still have
had scattered tumor cells, which are easily missed at
response assessment. Instead, a patient-centered outcome
should be preferred (ie, clinical complete response leading
to organ preservation). This would have required all pa-
tients to be evaluated for organ preservation before surgery,
which was not the case. These results can therefore not be
used to determine the impact of a radiation therapy boost
on organ preservation.
Conclusions
The RECTAL-BOOST trial may indicate that dose-
escalated chemoradiation with a radiation therapy boost
of 15 Gy to the tumor does not lead to more pathologic or
sustained clinical complete tumor responses in LARC. We
therefore suggest that the investigated dose-escalation
strategy currently has no role in the setting of neo-
adjuvant chemoradiation with planned surgery in LARC
patients. However, we showed a high rate of (near) com-
plete tumor regression after dose-escalated chemoradiation,
which encourages further investigation into the use of ra-
diation therapy to render more patients suitable for organ
preservation.
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